Treatments & Clinical Trials

Overview of stem cell approaches for MS—HSCT, MSCs, perinatal cells, and exosomes—clinical trial outcomes, safety and newborn stem cell banking options.

How cord blood stem cells treat rare genetic disorders, improve survival and neurological outcomes, and why banking at birth offers timely access to transplants.

MSC therapies for Crohn's fistulas show ~58% remission at 6 months; adipose and cord-derived cells are promising and generally well tolerated.

Examines clinical trials of stem cell treatments for degenerative disc disease, reporting structural regeneration, pain outcomes, safety, and emerging delivery and cell-free therapies.

Umbilical cord blood and exosomes reduce inflammation, activate satellite cells, and help restore muscle mass and function after aging or injury.

A concise overview of cord blood’s role in regenerative medicine, current uses, advances in cell expansion and gene editing, and challenges for banking and access.

How umbilical cord MSCs can reduce knee osteoarthritis pain, support cartilage repair, and show favorable safety when used alone or with HA/surgery.

Patient age, disease stage, immune biomarkers, and stem cell source and storage strongly affect autoimmune stem cell therapy outcomes.

Florida's new stem cell law (HB 1617) is creating regulated pathways for advanced therapies in the U.S. Learn how this shift makes banking cord blood and tissue more relevant than ever for your family's future health.